Clinical Trial

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

Study acronym: MAXILUS
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2023-09-13; most recent amendment 2026-06-12.
Status change: Recruiting → Active, Not Recruiting 2025-07-29
Status change: Not Yet Recruiting → Recruiting 2023-10-04
Trial Details
NCT Number NCT06045689
Lead Sponsor Bristol-Myers Squibb
Conditions Myelodysplastic Syndromes
Enrollment 106 participants
Start Date 2023-10-05
Primary Completion 2025-10-01 (estimated)
Study Completion 2027-09-29 (estimated)
Updated on ClinicalTrials.gov 2026-06-15